{"disease":{"id":"myelofibrosis-with-high-molecular-risk-mutations","name":"myelofibrosis with high molecular risk mutations"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07362225","title":"MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"MPN Research Foundation","has_results":false},{"nct_id":"NCT02598297","title":"Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations.","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":49,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}